Copy number variation analysis using next-generation sequencing identifies the <i>CFHR</i>3/<i>CFHR</i>1 deletion in atypical hemolytic uremic syndrome: a case report

Park, Joonhong; Yhim, Ho‐Young; Kang, Kyung Pyo; Bae, Tae Won; Cho, Yong Gon

doi:10.1080/16078454.2022.2075121

Cited by 3 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Annotation-specific genes shed light on the importance of build selection in the context of specific disorders. For example, hg19 and hg38-expressed CFHR-Factor H complex genes CFHR1 and CFHR3 are linked with atypical hemolytic uremic syndrome 36, 37 and fall within a region harboring population-specific copy number variations. The absence of these genes in CHM13 could be due to the reliance on a single cell line, especially in contrast to the genetic diversity from multiple cell lines underlying hg38 38 .…”

Section: Resultsmentioning

confidence: 99%

Impact of genome build on RNA-seq interpretation and diagnostics

Ungar,

Goddard,

Jensen

et al. 2024

Preprint

View full text Add to dashboard Cite

Transcriptomics is a powerful tool for unraveling the molecular effects of genetic variants and disease diagnosis. Prior studies have demonstrated that choice of genome build impacts variant interpretation and diagnostic yield for genomic analyses. To identify the extent genome build also impacts transcriptomics analyses, we studied the effect of the hg19, hg38, and CHM13 genome builds on expression quantification and outlier detection in 386 rare disease and familial control samples from both the Undiagnosed Diseases Network (UDN) and Genomics Research to Elucidate the Genetics of Rare Disease (GREGoR) Consortium. We identified 2,800 genes with build-dependent quantification across six routinely-collected biospecimens, including 1,391 protein-coding genes and 341 known rare disease genes. We further observed multiple genes that only have detectable expression in a subset of genome builds. Finally, we characterized how genome build impacts the detection of outlier transcriptomic events. Combined, we provide a database of genes impacted by build choice, and recommend that transcriptomics-guided analyses and diagnoses are cross-referenced with these data for robustness.

show abstract

Section: Resultsmentioning

confidence: 99%